Literature DB >> 24963346

Comparison of whole-body diffusion-weighted magnetic resonance and FDG-PET/CT in the assessment of Hodgkin's lymphoma for staging and treatment response.

Juan Montoro1, Daniele Laszlo1, Natalia Pin Chuen Zing1, Giuseppe Petralia2, Giorgio Conte3, Marzia Colandrea4, Giovanni Martinelli1, Lorenzo Preda2.   

Abstract

Computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and hybrid FDG-PET/CT are the most commonly used diagnostic tools for the initial staging and treatment response assessment of lymphomas [1]. The aim of this report is to compare the correlations between functional imaging markers derived from FDG-PET/CT and whole-body, diffusion-weighted magnetic resonance imaging (DW-MRI) in a young patient affected by Hodgkin's lymphoma (HL).

Entities:  

Keywords:  Hodgkin’s lymphoma; PET/CT; whole-body diffusion-weighted magnetic resonance

Year:  2014        PMID： 24963346      PMCID： PMC4027889          DOI： 10.3332/ecancer.2014.429

Source DB:  PubMed          Journal:  Ecancermedicalscience        ISSN： 1754-6605


  8 in total

1.  Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma.

Authors:  Maria Marzolini; Wai L Wong; Kirit Ardeshna; Anwar Padhani; Shirley D'Sa
Journal:  Br J Haematol       Date:  2011-12-08       Impact factor: 6.998

Review 2.  Magnetic resonance imaging of malignant lymphoma.

Authors:  Malou A Vermoolen; Marie José Kersten; Rob Fijnheer; Maarten S van Leeuwen; Thomas C Kwee; Rutger A J Nievelstein
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

Review 3.  Imaging in staging of malignant lymphoma: a systematic review.

Authors:  Thomas C Kwee; Robert M Kwee; Rutger A J Nievelstein
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

4.  Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma.

Authors:  Miroslav Herman; Boris Paucek; Ludek Raida; Miroslav Myslivecek; Jana Zapletalová
Journal:  Eur J Radiol       Date:  2007-05-02       Impact factor: 3.528

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Haematologica       Date:  2001-03       Impact factor: 9.941

7.  Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

Authors:  Michel Meignan; Andrea Gallamini; Michel Meignan; Andrea Gallamini; Corinne Haioun
Journal:  Leuk Lymphoma       Date:  2009-08

8.  Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma.

Authors:  Xingchen Wu; Hannu Pertovaara; Pasi Korkola; Prasun Dastidar; Ritva Järvenpää; Hannu Eskola; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240
  8 in total
  2 in total

1.  Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?

Authors:  Rodrigo Regacini; Andrea Puchnick; Flavio Augusto Vercillo Luisi; Henrique Manoel Lederman
Journal:  Pediatr Radiol       Date:  2018-01-23

Review 2.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.